The Microbial Contract Biomanufacturing Market Is Estimated To Be Worth USD 9.3 Billion In 2030, Predicts Roots Analysis


The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs


Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.”


The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

  • A detailed review of the current landscape of companies offering contract manufacturing services.
  • Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.
  • A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
  • An analysis of the partnerships and expansions that have been established in this domain, in the recent past.
  • A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
  • A detailed proprietary 2×2 representation to assess the current market scenario
  • An analysis of the initiatives of big biopharma players engaged in this domain.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Type of Product
  • API
  • FDF


  • Type of Biologic
  • Proteins
  • Enzymes
  • Growth Hormones
  • Antibody based Drugs
  • Others (plasmid DNA, probiotics, microbiome-based biologics)


  • Type of Microbial Expression System
  • Bacteria
  • Yeast
  • Others (Algae and fungi)


  • Scale of Operation
  • Commercial
  • Preclinical / Clinical


  • Type of End User
  • Small Companies
  • Mid-sized Companies
  • Large / Very Large Companies


  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific
  • Middle East and North Africa
  • Latin America


Transcripts of interviews held with the following senior level representatives of stakeholder companies



Key companies covered in the report

  • AGC Biologics
  • Aldevron
  • BioVectra
  • EirGenix
  • Etinpro
  • Eurogentec
  • Northway Biotechpharma
  • Ology Bioservices
  • Porton Biopharma
  • Stelis Biopharma


For additional details, please visit or email


You may also be interested in the following titles:

  1. Drug Repurposing Service Providers Market, 2020 – 2030
  2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
  3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030



Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091


Keywords: roots analysis,research,pharma,biotech,analysis,market research,industry reports,business report,global


Other related blogs

Why IV hydration therapy is the latest trend in cities

By : Replenish360

  If you feel lack of concentration and lethargic, understand that your body needs something e..

The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030, predicts Roots Analysis

By : Roots Analysis

Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), i..

AR / VR based Healthcare Digital Marketing Service Providers, 2020-2030

By : Roots Analysis

To order this 180+ page report, please visit this -